Findings

What do systematic reviews say?

493 questions · 509 findings · 56 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 149 · 29.3%GRADE not reported 9 · 1.8%Very low 128 · 25.1%Low 123 · 24.2%Moderate 79 · 15.5%High 21 · 4.1%

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.63 [0.12, 3.38]
1 study · 39 participants
Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Clinical improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 2.5 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.14 [0.79, 5.79]
1 study · 39 participants
Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.32 [0.04, 2.79]
1 study · 39 participants
Very low

Corticosteroids vs placebo

Endoscopic improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Clinical improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 2.5 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.56 [0.23, 1.37]
1 study · 40 participants
Very low

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Histological improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2 [0.2, 20.33]
1 study · 40 participants
Very low

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

Clinical improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found